Abstract: The invention is based upon the discovery that red blood cells contain phosphodiesterase 3B (PDE3B), and that inhibition of that phosphodiesterase allows for an enhanced accumulation of cAMP and subsequent release of ATP. It was further discovered that RBCs treated with insulin accumulate significantly less cAMP and release significantly less ATP than normal RBCs. Likewise, RBCs of patients suffering from type 2 diabetes (hyperinsulinemia) accumulate significantly less cAMP and release significantly less ATP than normal RBCs. It was further discovered that prostaglandin analogues synergistically work with phosphodiesterase 3B inhibitors to improve or increase cAMP accumulation and ATP release by RBCs. Thus the invention is directed to compositions and methods for improving ATP release by RBCs, via administering PDE3B inhibitor or a combination of PDE3B inhibitor and prostaglandin analogue.
Abstract: Contrary to current opinion that nitrite in general oxidizes hemoglobin with elimination of active nitric oxide, deoxygenated hemoglobin reacts with low concentration inorganic nitrite to produce very stable iron nitrosyl hemoglobin which on delivery into the body is converted to a hemoglobin capable of nitric oxide delivery and provides vasodilator and antiplatelet activity. This provides basis for ameliorated risk blood product transfusions.
Type:
Grant
Filed:
December 10, 2003
Date of Patent:
December 13, 2011
Assignees:
Montana State University-Bozeman, Duke University
Abstract: There is provided compositions and methods for the storage of red blood cells. The compositions are additive solutions comprising adenine, dextrose, mannitol, NaH2PO4, and optionally NaCl and/or NH4Cl. Composition are preferably used with oxygen-depletion refrigerated storage of red blood cells and may optionally be employed with nutrient supplements extending the useful shelf life of stored blood.
Abstract: A method for processing and preserving an acellular collagen-based tissue matrix for transplantation is disclosed. The method includes the steps of processing biological tissues with a stabilizing solution to reduce procurement damage, treatment with a processing solution to remove cells, treatment with a cryoprotectant solution followed by freezing, drying, storage and rehydration under conditions that preclude functionally significant damage and reconstitution with viable cells.
Type:
Grant
Filed:
June 7, 2002
Date of Patent:
November 29, 2011
Assignee:
LifeCell Corporation
Inventors:
Stephen A. Livesey, Anthony A. del Campo, Abhijit Nag, Ken B. Nichols, Edward S. Griffey, Christopher Coleman
Abstract: A method for storing and using platelets and an associated platelet structure. At least one modified platelet is formed. Each modified platelet includes a platelet and at least one polymerated chemical. Each polymerated chemical includes a polymer covalently bonded directly to the platelet or includes the polymer and a linker molecule such that the linker molecule is covalently bonded to the platelet and the polymer is covalently attached to the linker molecule. The polymer of each polymerated chemical of each modified platelet is polyethylene glycol (PEG) or a PEG derivative. Forming each modified platelet does not include modifying the platelet membrane of each platelet with a glycan-modifying agent. The at least one modified platelet is stored in a temperature range below 0° C. After being stored, the at least one modified platelet may be introduced into a subject to treat a condition related to a reduced platelet function.
Type:
Grant
Filed:
July 14, 2008
Date of Patent:
November 29, 2011
Assignee:
Canadian Blood Services
Inventors:
Elisabeth Maurer, Mark D. Scott, Nobu Kitamura
Abstract: A method for rapid, in-situ flushing of organs of a non-heart beating donor, and solutions for carrying out the flushing, are provided. The method initiates organ preservation, and the solutions are formulated to counteract basic mechanisms of ischemic cell injury, and to activate known biochemical survival pathways in the cell. Viability of the organ for transplant is thus maintained.
Abstract: The umbilical cord blood (UCB) compositions of the present invention possess the unique features of having plasma that is substantially depleted from the UCB unit and red blood cells (RBC) that are not depleted from the UCB unit. Such UCB units can be prepared by a process that combines plasma depletion with cryopreservation, selection, thawing, and/or transplantation of hematopoietic stem cells to provide superior clinical outcome by maximizing post-processing cell recovery and post-thaw infusion cell dose. Methods for treating a wide variety of malignant diseases and benign diseases associated with the hematopoietic system by administering the UCB compositions of the present invention are also provided.
Abstract: A method of providing autologous conditioned plasma (ACP) for treatment of connective tissue injuries. The method comprises the steps of: (i) providing an apparatus comprising a centrifuge and a double syringe, the double syringe including an inner syringe body and an outer syringe body; (ii) drawing autologous blood into the outer syringe body; (iii) subjecting the autologous blood to at least one centrifugation step to obtain an autologous conditioned plasma (ACP); (iv) removing, with the inner syringe body, at least a portion of autologous conditioned plasma (ACP) from the outer syringe body; and (v) inject ACP for treatment of various cartilage or tendon damage or diseases.
Type:
Grant
Filed:
December 21, 2007
Date of Patent:
November 8, 2011
Assignee:
Arthrex, Inc.
Inventors:
Michael Buhr, Werner Siekmann, Stèphane Naudin
Abstract: A method for preventing bacterial biofilm formation in a blood product, the method comprising modifying a blood product with a polymer selected from the group consisting of polyethylene glycol (PEG), PEG derivatives and mixtures thereof. Preventing bacterial biofilm formation in this way increases the planktonic to adherent ratio of any contaminating bacteria, and thereby facilitates detection of bacterial contamination.
Type:
Grant
Filed:
December 21, 2007
Date of Patent:
November 1, 2011
Assignee:
Canadian Blood Services
Inventors:
Sandra M. Ramirez-Arcos, Elisabeth Maurer, Mark Scott
Abstract: The umbilical cord blood (UCB) compositions of the present invention possess the unique features of having plasma that is substantially depleted from the UCB unit and red blood cells (RBC) that are not depleted from the UCB unit. Such UCB units can be prepared by a process that combines plasma depletion with cryopreservation, selection, thawing, and/or transplantation of hematopoietic stem cells to provide superior clinical outcome by maximizing post-processing cell recovery and post-thaw infusion cell dose. Methods for treating a wide variety of malignant diseases and benign diseases associated with the hematopoietic system by administering the UCB compositions of the present invention are also provided.
Abstract: Use of a composition which contains at least one semifluorinated alkane compound and at least one liquid siloxane, wherein the composition is of a density in a range of 0.8 to 1.5 g/cm3, for preserving organs or limbs.
Type:
Grant
Filed:
November 23, 2006
Date of Patent:
October 4, 2011
Assignee:
NOVALIQ GmbH
Inventors:
Hasso Meinert, Bernhard Günther, Wilfried Hiebl, Bastian Mühling, Daniel Brandhorst
Abstract: A method for lignocellulose conversion to sugar with improvements in yield and rate of sugar production has been developed by using ionic liquid pretreatment. This new pretreatment strategy substantially improves the efficiency (in terms of yield and reaction rates) of saccharification of lignocellulosic biomass. Cellulose and hemicellulose, when hydrolyzed into their sugars, can be converted into ethanol fuel through well established fermentation technologies. These sugars also form the feedstocks for production of variety of chemicals and polymers. The complex structure of biomass requires proper pretreatment to enable efficient saccharification of cellulose and hemicellulose components to their constituent sugars. Current pretreatment approaches suffer from slow reaction rates of cellulose hydrolysis (by using the enzyme cellulase) and low yields.
Type:
Grant
Filed:
March 13, 2008
Date of Patent:
October 4, 2011
Assignees:
The University of Toledo, Suganit Systems, Inc.
Inventors:
Sasidhar Varanasi, Constance Ann Schall, Anantharam Prasad Dadi, Jared Anderson, Kripa Rao, Guneet Kumar, Praveen Paripati
Abstract: Disclosed is a method of continuously producing ethanol and electricity from a sustainable renewable biomass feedstock in a processing plant contiguous to the acreage providing the biomass. The process is a closed loop operation having a dedicated crop grown year round producing multiple crops per acre. The renewable biomass feedstock is a sugar containing feedstock such as sweet sorghum. The biomass is grown year round and produces multiple crops per acre.
Abstract: A liquid plasma expander or resuscitation fluid composition for use in a subject in need thereof, comprising, consisting of; or consisting essentially of: (a) a keratin derivative (preferably alpha keratose, gamma keratose, or combinations thereof, and with basic alpha keratose preferred over acidic alpha keratose); and (b) an electrolyte solution, with the keratin derivative solubilized in the electrolyte solution to form a homogeneous liquid composition. Blood substitutes formed therefrom and methods of making and using the same are also described.
Abstract: The present invention relates to a pharmaceutical composition for the treatment of wounds containing blood plasma or serum and a method for treating wounds effectively by applying said composition to the wound site to normalize the tissue-environment around the site.
Type:
Grant
Filed:
December 12, 2006
Date of Patent:
September 13, 2011
Assignee:
Osiris Therapeutics, Inc.
Inventors:
Won Min Yoo, Kyung Hee Chang, Nae Choon Yoo, Ki Chang Keum, Sang Yup Lee, Gene Lee
Abstract: Living cellular material may be preserved by incubating the cellular material in a culture medium containing at least one sugar, particularly for at least three hours, and then subjecting the cellular material to a preservation protocol, such as freezing, vitrification, freeze-drying and desiccation.
Type:
Grant
Filed:
September 17, 2007
Date of Patent:
September 13, 2011
Assignee:
Organ Recovery Systems, Inc.
Inventors:
Kelvin G. M. Brockbank, Lia H. Campbell, Kelly M. Ratcliff, Kristy A. Sarver
Abstract: A composition for protecting and/or preserving cells, tissues or organs, includes at least one cyclodextrin, preferably closely combined with an antioxidant. A process for producing this composition and its uses are also disclosed.
Type:
Grant
Filed:
December 12, 2007
Date of Patent:
September 13, 2011
Assignees:
Biocydex, Universite de Poitiers, Centre Hospitalier Universitaire de Poitiers, Institut National Sante Recherche Medicale
Inventors:
Yves Cenatiempo, El Mustapha Belgsir, Manilduth Ramnath, Frédéric Favreau, Michel Carretier, Gérard Mauco, Thierry Hauet
Abstract: Disclosed is a method for production of an optically active biphenylalanine compound represented by the formula (2): (wherein, R2 is a protective group of an amino group, and R3 and R4 are each independently a hydrogen atom, etc.) or a salt thereof and an optically active biphenylalanine ester compound represented by the formula (3): (wherein, R1 is an alkyl group, etc.) wherein the method comprises hydrolyzing a biphenylalanine ester compound represented by the formula (1): with a protease produced by a microorganism belonging to Bacillus sp. in the presence of at least one alkali selected from an alkali metal hydroxide and an alkaline earth metal hydroxide.
Abstract: The present invention relates to a method for producing fatty acid alkyl esters, such as fatty acid methyl esters (FAME) and fatty acid ethyl esters with a low level of impurities such as phospholipids. The method of the invention is simplified by combining two process steps into one single process step and is therefore economically cheaper. The method includes mixing water, alcohol, triglyceride and/or free fatty acids a lipolytic enzyme and a phospholipase. Subsequently the aqueous phase, which contains glycerine, residual enzyme and most of the hydrolyzed phospholipids, is separated from the non-aqueous phase, whereby the content of phospholipids in the non-aqueous phase is reduced.
Type:
Grant
Filed:
June 13, 2006
Date of Patent:
September 6, 2011
Assignee:
Novozymes A/S
Inventors:
Hans Christian Holm, Per Munk Nielsen, Morten Wurtz Christensen
Abstract: An evaluation and preservation solution for human and animal organs, tissues and parts thereof is described, wherein it comprises serum albumin at a concentration of 55-105 g/L, a scavenger and coating compound, preferably dextran compounds and derivatives thereof having essentially the same structure at a concentration of 1-55 g/L weight, and a physiological serum concentration of salts and nutrients in a physiologically acceptable medium.